Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data
Not available.
Saved in:
Similar Items
-
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients
by: Gregorio Barilà, et al.
Published: (2025-04-01) -
Ensiling as a Conservation Technique for <i>Opuntia ficus indica</i> (L.) By-Products: Peel and Pastazzo
by: Riccardo Gannuscio, et al.
Published: (2024-11-01) -
Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. <i>Pharmaceuticals</i> 2025, <i>18</i>, 595
by: Nicola Sgherza, et al.
Published: (2025-06-01) -
NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?
by: Alessandro Corso, et al.
Published: (2017-08-01) -
A New Algorithm for the Global-Scale Quantification of Volcanic SO<sub>2</sub> Exploiting the Sentinel-5P TROPOMI and Google Earth Engine
by: Maddalena Dozzo, et al.
Published: (2025-02-01)